-DOCSTART- -X- O
A -X- _ O
better -X- _ O
understanding -X- _ O
of -X- _ O
the -X- _ O
seroprevalence -X- _ O
and -X- _ O
specificity -X- _ O
of -X- _ O
influenza -X- _ O
HA -X- _ O
stem-directed -X- _ O
broadly -X- _ O
neutralizing -X- _ O
antibodies -X- _ O
( -X- _ O
bNAbs -X- _ O
) -X- _ O
in -X- _ O
the -X- _ O
human -X- _ O
population -X- _ O
could -X- _ O
significantly -X- _ O
inform -X- _ O
influenza -X- _ O
vaccine -X- _ O
design -X- _ O
efforts. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
utilized -X- _ O
probes -X- _ O
comprising -X- _ O
headless -X- _ B-Intervention
, -X- _ I-Intervention
HA -X- _ I-Intervention
stabilized -X- _ I-Intervention
stem -X- _ I-Intervention
( -X- _ I-Intervention
SS -X- _ I-Intervention
) -X- _ I-Intervention
to -X- _ O
determine -X- _ O
the -X- _ O
prevalence -X- _ O
, -X- _ O
binding -X- _ O
and -X- _ O
neutralization -X- _ O
breadth -X- _ O
of -X- _ O
antibodies -X- _ O
directed -X- _ O
to -X- _ O
HA -X- _ O
stem-epitope -X- _ O
in -X- _ O
a -X- _ O
cross-sectional -X- _ O
analysis -X- _ O
of -X- _ O
the -X- _ O
general -X- _ B-Patient
population. -X- _ I-Patient
Five -X- _ O
group-1 -X- _ O
HA -X- _ O
SS -X- _ O
probes -X- _ O
, -X- _ O
representing -X- _ O
five -X- _ O
subtypes -X- _ O
, -X- _ O
were -X- _ O
chosen -X- _ O
for -X- _ O
this -X- _ O
analyses. -X- _ O
Eighty-four -X- _ O
percent -X- _ O
of -X- _ O
samples -X- _ O
analyzed -X- _ O
had -X- _ O
specific -X- _ O
reactivity -X- _ O
to -X- _ O
at -X- _ O
least -X- _ O
one -X- _ O
probe -X- _ O
, -X- _ O
with -X- _ O
approximately -X- _ O
60 -X- _ O
% -X- _ O
of -X- _ O
the -X- _ O
samples -X- _ O
reactive -X- _ O
to -X- _ O
H1 -X- _ O
probes -X- _ O
, -X- _ O
and -X- _ O
up -X- _ O
to -X- _ O
45 -X- _ O
% -X- _ O
reactive -X- _ O
to -X- _ O
each -X- _ O
of -X- _ O
the -X- _ O
non-circulating -X- _ O
subtypes. -X- _ O
Thirty -X- _ O
percent -X- _ O
of -X- _ O
analyzed -X- _ O
sera -X- _ O
had -X- _ O
cross-reactivity -X- _ O
to -X- _ O
at -X- _ O
least -X- _ O
four -X- _ O
of -X- _ O
five -X- _ O
probes -X- _ O
and -X- _ O
this -X- _ O
reactivity -X- _ O
could -X- _ O
be -X- _ O
blocked -X- _ O
by -X- _ O
competing -X- _ O
with -X- _ O
F10 -X- _ O
bNAb. -X- _ O
Binding -X- _ O
cross-reactivity -X- _ B-Outcome
in -X- _ I-Outcome
sera -X- _ I-Outcome
samples -X- _ I-Outcome
significantly -X- _ I-Outcome
correlated -X- _ I-Outcome
with -X- _ I-Outcome
frequency -X- _ I-Outcome
of -X- _ I-Outcome
H1 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
H5 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
cross-reactive -X- _ I-Outcome
B -X- _ I-Outcome
cells. -X- _ I-Outcome
Interestingly -X- _ O
, -X- _ O
only -X- _ B-Outcome
33 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
cross-reactive -X- _ I-Outcome
sera -X- _ I-Outcome
neutralized -X- _ I-Outcome
both -X- _ I-Outcome
H1N1 -X- _ I-Outcome
and -X- _ I-Outcome
H5N1 -X- _ I-Outcome
pseudoviruses. -X- _ I-Outcome
Cross-reactive -X- _ B-Outcome
and -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibodies -X- _ I-Outcome
were -X- _ I-Outcome
more -X- _ I-Outcome
prevalent -X- _ I-Outcome
in -X- _ I-Outcome
individuals -X- _ I-Outcome
> -X- _ I-Outcome
50 -X- _ I-Outcome
years -X- _ I-Outcome
of -X- _ I-Outcome
age. -X- _ I-Outcome
Our -X- _ O
data -X- _ O
demonstrate -X- _ O
the -X- _ O
need -X- _ O
to -X- _ O
use -X- _ O
multiple -X- _ O
HA-stem -X- _ O
probes -X- _ O
to -X- _ O
assess -X- _ O
for -X- _ O
broadly -X- _ O
reactive -X- _ O
antibodies. -X- _ O
Further -X- _ O
, -X- _ O
a -X- _ O
universal -X- _ B-Outcome
vaccine -X- _ I-Outcome
could -X- _ I-Outcome
be -X- _ I-Outcome
designed -X- _ I-Outcome
to -X- _ I-Outcome
boost -X- _ I-Outcome
pre-existing -X- _ I-Outcome
B-cells -X- _ I-Outcome
expressing -X- _ I-Outcome
stem-directed -X- _ I-Outcome
bNAbs -X- _ I-Outcome
. -X- _ O

